Key Insights

Highlights

Success Rate

100% trial completion (above average)

Treatment Research

3 treatments under study, led by Fluzone

Related Conditions

Often studied with 4 related conditions

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 2 trials

Success Rate

100.0%

+13.4% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed with results

Key Signals

100% success

Data Visualizations

Phase Distribution

Trial Status

Completed2

Trial Success Rate

100.0%

Benchmark: 86.6%

Based on 2 completed trials

Clinical Trials (2)

Showing 2 of 2 trials
NCT01046331Completed

Novel Influenza A (H1N1) Surveillance Registry

NCT01484522Completed

Laboratory Study of Licensed H1N1 Influenza Vaccines in HIV-1 Perinatally Infected Children and Youth

Showing all 2 trials

Research Network

Common Treatments

  • Fluzone1
  • Fluvirin1
  • Flumist1

Active Sponsors

  • National Institute of Allergy and Infectious Diseases (NIAID)1
  • International Maternal Pediatric Adolescent AIDS Clinical Trials Group1
  • National Heart, Lung, and Blood Institute (NHLBI)1

Top Investigators

Related Conditions

  • Influenza2
  • Novel Influenza A1
  • Flu1
  • Hiv1 Infection1

Activity Timeline